MXCT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MX

Mkt Cap

$133.7M

Volume

964.80K

Next Earnings

November 10th

Loading chart

MX

MXCTMaxCyte, Inc. Common Stock

MXCT

Pay with—

Available Balance0.00

MX

Mkt Cap

$134.2M

Volume

964.80K

Next Earnings

November 10th

Chart Financials Earnings News About Insider Filings

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.Zacks Investment Research · Oct 6, 2026

North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion OpportunityThe North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.GlobeNewswire Inc. · Sep 30, 2026

Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED)U.S. stock futures showed mixed performance on Wednesday with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose. President Trump visited China with major tech leaders including Nvidia's Jensen Huang, Tesla's Elon Musk, and Apple's Tim Cook. Key movers included Nextpower surging on strong earnings, MaxCyte jumping on better-than-expected results, and Red Cat Holdings plunging after a public offering announcement. The 10-year Treasury yield stood at 4.46%, with markets pricing a 97.6% likelihood of unchanged Fed rates in June.Benzinga · May 13, 2026

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsMaxCyte reported preliminary 2025 financial results with core revenue of $29.5-29.6 million for the full year, in line with guidance despite a challenging macro environment. The company ended the year with approximately $155.6 million in cash and investments, significantly reduced annual burn, and a restructured organization. Management expects to return to revenue growth in the second half of 2026 with new product offerings launching early in the year.Benzinga · Jan 12, 2026

Global Transfection Technologies Market Predicted to Surpass USD 2.33 billion, at a CAGR of 9.0% by 2032 - Report ... - GlobeNewswireThe global transfection technologies market is expected to grow at a CAGR of 9.0% from 2024 to 2032, driven by the rising demand for protein production and advancements in biotechnology.GlobeNewswire Inc. · Jul 4, 2024

Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Zacks Investment Research · Jun 13, 2024

Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's WhyMaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.Zacks Investment Research · Jun 13, 2024

MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT.GlobeNewswire Inc. · May 29, 2024

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentLegend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells. Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.GlobeNewswire Inc. · May 22, 2024

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue EstimatesMaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 7, 2024

to start trading

MX

MXCTMaxCyte, Inc. Common Stock

MXCT

Pay with—

Available Balance0.00

Your PositionYou don't own any MXCT yet.

Related Tickers

Earnings